Literature DB >> 25888271

Is dexamethasone a better partner for abiraterone than prednisolone?

Omer Dizdar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25888271      PMCID： PMC4425392          DOI： 10.1634/theoncologist.2014-0472

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

Review 1.  Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  Richard J Auchus; Margaret K Yu; Suzanne Nguyen; Suneel D Mundle
Journal:  Oncologist       Date:  2014-10-31

Review 2.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases.

Authors:  S Diederich; T Scholz; E Eigendorff; Ch Bumke-Vogt; M Quinkler; P Exner; A F Pfeiffer; W Oelkers; V Bähr
Journal:  Horm Metab Res       Date:  2004-06       Impact factor: 2.936

4.  A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

Authors:  Ramachandran Venkitaraman; David Lorente; Vedang Murthy; Karen Thomas; Lydia Parker; Ruth Ahiabor; David Dearnaley; Robert Huddart; Johann De Bono; Chris Parker
Journal:  Eur Urol       Date:  2014-10-16       Impact factor: 20.096

5.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Authors:  D Bianchini; D Lorente; A Rodriguez-Vida; A Omlin; C Pezaro; R Ferraldeschi; A Zivi; G Attard; S Chowdhury; J S de Bono
Journal:  Eur J Cancer       Date:  2013-09-25       Impact factor: 9.162

6.  Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.

Authors:  D Lorente; A Omlin; R Ferraldeschi; C Pezaro; R Perez; J Mateo; A Altavilla; Z Zafeirou; N Tunariu; C Parker; D Dearnaley; S Gillessen; J de Bono; G Attard
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640
  6 in total
  4 in total

1.  In reply.

Authors:  Richard J Auchus; Margaret K Yu; Suzanne Nguyen; Suneel D Mundle
Journal:  Oncologist       Date:  2015-04-17

Review 2.  Corticosteroid switch after progression on abiraterone acetate plus prednisone.

Authors:  Giandomenico Roviello; Navid Sobhani; Silvia Paola Corona; Alberto D'Angelo
Journal:  Int J Clin Oncol       Date:  2019-11-08       Impact factor: 3.402

3.  Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.

Authors:  Giandomenico Roviello; Roberto Petrioli; Alberto Bonetta; Raffaele Conca; Maria Grazia Rodriquenz; Michele Aieta
Journal:  Invest New Drugs       Date:  2018-10-22       Impact factor: 3.850

4.  Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.

Authors:  Yu-Chao Ni; Jin-Ge Zhao; Meng-Ni Zhang; Yi-Jun Zhang; Zhen-Yu Yang; Ni Chen; Jun-Ru Chen; Peng-Fei Shen; Guang-Xi Sun; Xing-Ming Zhang; Yong-Hong Li; Hao Zeng
Journal:  Asian J Androl       Date:  2022 Mar-Apr       Impact factor: 3.285
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.